Ye-Jin Kim

Ye-Jin Kim

University of Pennsylvania

H-index: 13

North America-United States

About Ye-Jin Kim

Ye-Jin Kim, With an exceptional h-index of 13 and a recent h-index of 12 (since 2020), a distinguished researcher at University of Pennsylvania, specializes in the field of Cancer biology, Onco-immunology, Antibody.

His recent articles reflect a diverse array of research interests and contributions to the field:

Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same

Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates

IL-21 (heterodimeric Fc-fused IL-21) fused to immunoglobulin heavy chain constant region heterodimer (heterodimeric Fc), and pharmaceutical composition comprising same

Discovery and pre-clinical evaluation of antibodies to the NKG2A inhibitory receptor

A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo

The copper chaperone CCS facilitates copper binding to MEK1/2 to promote kinase activation

Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAFV600E-Driven Melanoma

A neuropilin-1 antagonist exerts antitumor immunity by inhibiting the suppressive function of intratumoral regulatory T cells

Ye-Jin Kim Information

University

Position

___

Citations(all)

553

Citations(since 2020)

445

Cited By

260

hIndex(all)

13

hIndex(since 2020)

12

i10Index(all)

14

i10Index(since 2020)

14

Email

University Profile Page

Google Scholar

Ye-Jin Kim Skills & Research Interests

Cancer biology

Onco-immunology

Antibody

Top articles of Ye-Jin Kim

Title

Journal

Author(s)

Publication Date

Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same

2023/7/4

Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates

Frontiers in Oncology

Ye-Jin Kim

Wei Li

Doncho V Zhelev

John W Mellors

Dimiter S Dimitrov

...

2023/2/27

IL-21 (heterodimeric Fc-fused IL-21) fused to immunoglobulin heavy chain constant region heterodimer (heterodimeric Fc), and pharmaceutical composition comprising same

2022/10/4

Discovery and pre-clinical evaluation of antibodies to the NKG2A inhibitory receptor

bioRxiv

Du-San Baek

Ye-Jin Kim

Wei Li

Bernard JC Macatangay

Joshua C Cyktor

...

2022/5/19

A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo

Cancer letters

Du-San Baek

Ye-Jin Kim

Sandra Vergara

Alex Conard

Cynthia Adams

...

2022/1/28

The copper chaperone CCS facilitates copper binding to MEK1/2 to promote kinase activation

Journal of Biological Chemistry

Michael Grasso

Gavin J Bond

Ye-Jin Kim

Stefanie Boyd

Maria Matson Dzebo

...

2021/12/1

Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAFV600E-Driven Melanoma

Cancer research

Ye-Jin Kim

Tiffany Tsang

Grace R Anderson

Jessica M Posimo

Donita C Brady

2020/4/2

A neuropilin-1 antagonist exerts antitumor immunity by inhibiting the suppressive function of intratumoral regulatory T cells

Cancer Immunology Research

Keunok Jung

Jeong-Ah Kim

Ye-Jin Kim

Hyun Woo Lee

Chul-Ho Kim

...

2020/1/1

Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection

Proceedings of the National Academy of Sciences

Wei Li

Chuan Chen

Aleksandra Drelich

David R Martinez

Lisa E Gralinski

...

2020/11/24

Structural and molecular determinants of CCS-mediated copper activation of MEK1/2

Michael Grasso

Gavin J Bond

Ye-Jin Kim

Katherine B Alwan

Stefanie Boyd

...

2020/5/2

See List of Professors in Ye-Jin Kim University(University of Pennsylvania)